Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liverHBVDNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as aRIG-Iagonist to activate cellular innate immune responses^[1][2].

Target: HBV^[1]

Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B^[2].

Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values^[1].

587.50

Solid

C₂₀H₂₆N₇O₁₀PS

475650-36-3

Room temperature in continental US; may vary elsewhere.

DMSO : 200 mg/mL(340.43 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 5% DMSO    40%PEG300   5%Tween-80   50% saline

  Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
• 2.

  请依序添加每种溶剂： 5% DMSO    95% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
• 3.

  请依序添加每种溶剂： 1% DMSO    99% saline

  Solubility: ≥ 0.25 mg/mL (0.43 mM); Clear solution